// App-Quantinova.ai

2698 : Effectiveness and Safety Outcomes in Patients with Hemophilia a Receiving Antihemophilic Factor (Recombinant) for at Least 5 Years in a Real-World Setting: 6-Year Interim Analysis of the Ahead International and German Studies

Researchers

Presenter

  • Dimitrios A. Tsakiris

Principal Investigators

  • Johannes Oldenburg

  • Robert Klamroth

  • Benot Guillet

  • Kate Khair

  • Angela Huth-Khne

  • Karin Kurnik

  • Stephan Regensburger

  • Jaco Botha

  • Alejandro Fernandez

  • Leilei Tang

  • Margareth C. Ozelo

Medical Centers

  • Diagnostic Hematology, University Hospital Basel, Basel, Switzerland

  • Institute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Bonn, Germany

  • Department for Internal Medicine, Vascular Medicine and Haemostaseology, Vivantes Klinikum Friedrichshain, Berlin, Germany

  • Hemophilia Treatment Centre, Inserm U1085 IRSET, University Hospital of Rennes, Rennes, France

  • Centre for Outcomes and Experience Research in Children's Health, Illness and Disability (ORCHID), Great Ormond Street Hospital for Children, NHS Foundation Trust, London, United Kingdom

  • SRH Kurpfalzkrankenhaus and Haemophilia Centre Heidelberg GmbH, Heidelberg

  • Dr. von Haunersches Kinderspital Klinikum der Universität München, München, Germany

  • Takeda Pharma Vertrieb GmbH & Co. KG,Berlin,Germany

  • Takeda Pharmaceutical International AG, Zürich, Switzerland

  • Neurology, University of Campinas, Campinas, Brazil

Locations

  • Switzerland

  • Germany

  • France

  • United Kingdom

  • Brazil

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Hemophilia

Biomarkers

  • N/A

Drug/Treatment

  • Antihemophilic factor

Outcome

  • N/A

Study Design

  • Non Interventional

  • Multinational

  • Multicenteric

  • Prospective

Phase

  • NA

Study Id's

  • NCT02078427

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved